Tau induces inflammasome activation and microgliosis through acetylating NLRP3

Lun Zhang, Yongkang Gai, Yushuang Liu, Dongli Meng, Yi Zeng, Yong Luo, Huiliang Zhang, Zhuoqun Wang, Mengzhe Yang, Yunfan Li, Yi Liu, Yi‐Wen Lai, Jiayu Yang, Gang Wu, Yu Chen, Jingtan Zhu, Shaojun Liu, Tingting Yu, Ji Zeng, Jian‐Zhi Wang, Dan Zhu, Xiaochuan Wang, Xiaoli Lan, Rong LiuClinical 2024 · DOI

TL;DR

This study reveals a novel mechanism where pathological Tau protein directly acetylates NLRP3, a key component of the inflammasome, leading to microglial activation and neuroinflammation in Alzheimer's disease (AD) and related tauopathies. This discovery offers a potential therapeutic target for early intervention by blocking this Tau-NLRP3 interaction.

What Problem Does This Paper Address?

Alzheimer's disease (AD) and other tauopathies are characterized by the abnormal accumulation of tau protein, which is closely linked to neuroinflammation driven by activated microglia. However, the precise molecular mechanisms by which tau pathology triggers microglial activation and the causal relationship between them have remained largely elusive. This paper aims to elucidate this critical link, specifically investigating how tau might directly influence the inflammasome pathway, a central player in neuroinflammation.

Methods

The researchers employed a multi-pronged approach:

  • In vitro assays: They used cell culture models (HEK-293T and BV-2 microglial cells) to investigate the direct interaction between tau and NLRP3, as well as the functional consequences of this interaction. Techniques included:
  • Western blotting and ELISA: To measure protein levels of NLRP3, ASC, Caspase-1, and IL-1β, and to assess NLRP3 acetylation.
  • Co-immunoprecipitation (Co-IP) and immunofluorescence (IF) staining: To confirm direct binding and cellular localization of tau and NLRP3.
  • Test-tube acetylation assay and mass spectrometry: To pinpoint specific acetylation sites on NLRP3 and confirm tau's acetyltransferase activity.
  • Molecular docking: To predict the interaction interface between tau and NLRP3.
  • In vivo models: They utilized transgenic mouse models (3xTg-AD and PS19 mice) and genetically engineered mice overexpressing specific tau variants (Tau441, TauS262E, TauK18-) in the hippocampus. These models were used to:
  • Assess cognitive function: Through behavioral tests like the Novel Object Recognition (NOR), Fear Conditioning Test (FCT), and Morris Water Maze (MWM).
  • Evaluate neuroinflammation: Using PET/CT imaging with an 18F-labeled tracer for microglial activation and Iba-1 staining for microglial morphology.
  • Investigate therapeutic intervention: A designed peptide (TNB) was used to block tau-NLRP3 interaction and its effects were assessed.
  • Human samples: Hippocampal tissues from AD patients were analyzed to correlate findings with human disease.

Datasets

The study utilized:

  • Human brain samples: From AD patients and control individuals.
  • Mouse models:
    • 3xTg-AD mice (9-month old)
    • PS19 mice (3- and 6-month old)
    • C57BL/6 mice (wild-type)
    • Mice with AAV-mediated overexpression of Tau441, TauS262E, and TauK18- in the hippocampus.
  • Cell lines: HEK-293T, N2a, SH-SY5Y, and BV-2 microglial cells.

No new benchmark datasets were introduced; rather, existing models and established behavioral and imaging techniques were employed.

Key Insights and Ideas

  • Tau as a direct NLRP3 acetylator: The most striking finding is that tau protein, particularly certain phosphorylated forms, directly acetylates NLRP3. This challenges the previous understanding that inflammasome activation is solely triggered by aggregated tau or other pathological insults.
  • K21, K22, and K24 on NLRP3 are critical sites: The study pinpoints specific lysine residues on the NLRP3 PYD domain as key targets for tau-mediated acetylation, which is essential for inflammasome activation.
  • A vicious cycle of neuroinflammation: The research suggests a feedback loop where tau pathology drives NLRP3 inflammasome activation in microglia, leading to neuroinflammation, which in turn may exacerbate tau pathology.
  • Therapeutic potential of blocking Tau-NLRP3 interaction: The development and successful testing of a TNB peptide that inhibits tau-NLRP3 binding and downstream effects highlight a promising avenue for early therapeutic intervention in tauopathies.

Key Results

  • Elevated NLRP3 acetylation and inflammasome activation: Observed in 3xTg-AD mice, PS19 mice, and AD patients, correlating strongly with tau/p-tau levels.
  • Tau/p-tau promotes NLRP3 acetylation: In vitro, tau and specific p-tau mimics (TauT181E, TauS199E, TauT217E, TauS262E) significantly increased NLRP3 acetylation and inflammasome activation in BV-2 cells. TauS262E showed the strongest effect.
  • Direct acetylation of NLRP3 by Tau: Confirmed through in vitro assays, showing tau directly acetylates NLRP3 at K21, K22, and K24 sites.
  • Tau overexpression impairs cognition and activates microglia: In mice, hippocampal overexpression of Tau441 and TauS262E led to cognitive deficits, increased NLRP3 acetylation, inflammasome activation, and reactive microgliosis. TauK18-, lacking acetyltransferase activity, did not induce these effects.
  • TNB peptide ameliorates pathology: In vivo, the TNB peptide significantly reduced NLRP3 acetylation, inflammasome activation, microgliosis, and rescued cognitive impairment in tau-overexpressing mice.

Limitations and Future Work

  • Specificity of Tau variants: While the study highlights TauS262E as particularly potent, further investigation into the differential effects of various tau post-translational modifications and aggregation states on NLRP3 acetylation would be beneficial.
  • In vivo TNB peptide delivery: While effective, optimizing the delivery and targeting of the TNB peptide for broader therapeutic application in the brain could be a future direction.
  • Mechanisms of IL-1β priming: The paper acknowledges that while it elucidates the role of tau in NLRP3 activation, the upstream mechanisms of IL-1β priming in this context could be further explored.
  • Broader therapeutic implications: The authors suggest that targeting NLRP3 acetylation induced by tau could be a promising strategy for early AD and tauopathy therapy, implying further preclinical and clinical development is warranted.

Summary updated

Abstract

In conclusion, our findings provide evidence for a novel role of Tau in the regulation of microglia activation through acetylating NLRP3, which has potential implications for early intervention and personalised treatment of AD and related Tauopathies.
BibTeX
@inproceedings{zhang2024tau,
  author = {Lun Zhang and Yongkang Gai and Yushuang Liu and Dongli Meng and Yi Zeng and Yong Luo and Huiliang Zhang and Zhuoqun Wang and Mengzhe Yang and Yunfan Li and Yi Liu and Yi‐Wen Lai and Jiayu Yang and Gang Wu and Yu Chen and Jingtan Zhu and Shaojun Liu and Tingting Yu and Ji Zeng and Jian‐Zhi Wang and Dan Zhu and Xiaochuan Wang and Xiaoli Lan and Rong Liu},
  title = {{Tau induces inflammasome activation and microgliosis through acetylating NLRP3}},
  booktitle = {Clinical},
  year = {2024},
  doi = {10.1002/ctm2.1623},
}
Figure